|
[1]
|
Cheng, X., et al. (2021) Adjuvant Albumin-Bound Paclitaxel Combined with S-1 vs. Oxaliplatin Combined with Capecitabine after D2 Gastrectomy in Patients with Stage III Gastric Adenocarcinoma: A Phase III Multicenter, Open-Label, Randomized Controlled Clinical Trial Protocol. BMC Cancer, 21, Article No. 56. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Ajani, J.A., et al. (2013) Gastric Cancer, Version 2.2013. Journal of the National Comprehensive Cancer Network, 11, 531-546.
|
|
[3]
|
吕豪. 局部进展期胃癌新辅助化疗临床疗效评估及相关影响因素分析[D]: [硕士学位论文]. 开封: 河南大学, 2020.[CrossRef]
|
|
[4]
|
Isobe, Y., et al. (2011) Gastric Cancer Treatment in Japan: 2008 Annual Report of the JGCA Nationwide Registry. Gastric Cancer, 14, 301-316. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
He, M., et al. (2018) Phase II Clinical Trial of S-1 plus Nanopar-ticle Albumin-Bound Paclitaxel in Untreated Patients with Metastatic Gastric Cancer. Cancer Science, 109, 3575-3582. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Shitara, K., et al. (2017) Nab-Paclitaxel versus Solvent-Based Paclitaxel in Patients with Previously Treated Advanced Gastric Cancer (ABSOLUTE): An Open-Label, Randomised, Non-Inferiority, Phase 3 Trial. The Lancet Gastroenterology & Hepatology, 2, 277-287. [Google Scholar] [CrossRef]
|
|
[7]
|
Katsaounis, P. (2017) Nab-Paclitaxel as Second-Line Treatment in Advanced Gastric Cancer: A Multicenter Phase II Study of the Hellenic Oncology Research Group. Annals of Gastroenterology, 31, 65-70. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Bando, H., et al. (2018) A Phase II Study of Nab-Paclitaxel in Combination with Ramucirumab in Patients with Previously Treated Advanced Gastric Cancer. European Journal of Cancer, 91, 86-91. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Kawamoto, Y., et al. (2017) Study Protocol of HGCSG1404 SNOW Study: A Phase I/II Trial of Combined Chemotherapy of S-1, Nab-Paclitaxel and Oxaliplatin Administered Bi-weekly to Patients with Advanced Gastric Cancer. BMC Cancer, 17, Article No. 837. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Ford, H.E.R., et al. (2014) Docetaxel versus Active Symptom Control for Refractory Oesophagogastric Adenocarcinoma (COUGAR-02): An Open-Label, Phase 3 Randomised Controlled Trial. The Lancet Oncology, 15, 78-86. [Google Scholar] [CrossRef]
|
|
[11]
|
Roviello, G., et al. (2019) Nanoparticle Albumin-Bound Paclitaxel: A Big Nano for the Treatment of Gastric Cancer. Cancer Chemotherapy and Pharmacology, 84, 669-677. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Gelderblom, H., Verweij, J., Nooter, K. and Sparreboom, A. (2001) Cremophor EL: The Drawbacks and Advantages of Vehicle Selection for Drug Formulation. European Journal of Cancer, 37, 1590-158. [Google Scholar] [CrossRef]
|
|
[13]
|
Hidalgo, M., et al. (2015) SPARC Expression Did Not Predict Efficacy of Nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Ex-ploratory Analysis of the Phase III MPACT Trial. Clinical Cancer Research, 21, 4811-4818. [Google Scholar] [CrossRef]
|
|
[14]
|
Desai, N., Trieu, V., Damascelli, B. and Soon-Shiong, P. (2009) SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Translational Oncology, 2, 59-64. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Schettini, F., Giuliano, M., De Placido, S. and Arpino, G. (2016) Nab-Paclitaxel for the Treatment of Triple-Negative Breast Cancer: Rationale, Clinical Data and Future Perspectives. Cancer Treatment Reviews, 50, 129-141. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
ten Tije, A.J., Verweij, J., Loos, W.J. and Sparreboom, A. (2003) Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy. Clinical Pharmacokinetics, 42, 665-685. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Gradishar, W.J., et al. (2005) Phase III Trial of Nano-particle Albumin-Bound Paclitaxel Compared with Polyethylated Castor Oil-Based Paclitaxel in Women with Breast Cancer. JCO, 23, 7794-7803. [Google Scholar] [CrossRef]
|
|
[18]
|
Desai, N., et al. (2006) Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel. Clinical Cancer Research, 12, 1317-1324. [Google Scholar] [CrossRef]
|
|
[19]
|
Gardner, E.R., et al. (2008) Randomized Crossover Phar-macokinetic Study of Solvent-Based Paclitaxel and Nab-Paclitaxel. Clinical Cancer Research, 14, 4200-4205. [Google Scholar] [CrossRef]
|
|
[20]
|
Watson, S., et al. (2019) Oxaliplatin, 5-Fluorouracil and Nab-Paclitaxel as Perioperative Regimen in Patients with Resectable Gastric Adenocarcinoma: A GERCOR Phase II Study (FOXAGAST). European Journal of Cancer, 107, 46-52. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Nakamura, M., et al. (2021) Phase 1 Study of Combined of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study). Oncology, 99, 57-61. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Sasaki, Y., et al. (2014) Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel as Second-Line Chemotherapy for Unresectable or Recurrent Gastric Cancer. Cancer Science, 105, 812-817. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Ibrahim, N.K., et al. (2005) Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women with Metastatic Breast Cancer. JCO, 23, 6019-6026. [Google Scholar] [CrossRef]
|
|
[24]
|
Sato, S., et al. (2018) A Phase II Study of Tri-Weekly Low-Dose Nab-Paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer. Anticancer Research, 38, 6911-6917. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Xiong, J., Han, S., Ding, S., He, J. and Zhang, H. (2018) Anti-body-Nanoparticle Conjugate Constructed with Trastuzumab and Nanoparticle Albumin-Bound Paclitaxel for Targeted Therapy of Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer. Oncology Reports, 39, 1396-1404. [Google Scholar] [CrossRef] [PubMed]
|